Literature DB >> 12018806

Neurologic complications of prostate cancer.

Ramsis Benjamin1.   

Abstract

Neurologic complications continue to pose problems in patients with metastatic prostate cancer. From 15 to 30 percent of metastases are the result of prostate cancer cells traveling through Batson's plexus to the lumbar spine. Metastatic disease in the lumbar area can cause spinal cord compression. Metastasis to the dura and adjacent parenchyma occurs in 1 to 2 percent of patients with metastatic prostate cancer and is more common in those with tumors that do not respond to hormone-deprivation therapy. Leptomeningeal carcinomatosis, the most frequent form of brain metastasis in prostate cancer, has a grim prognosis. Because neurologic complications of metastatic prostate cancer require prompt treatment, early recognition is important. Physicians should consider metastasis in the differential diagnosis of new-onset low back pain or headache in men more than 50 years of age. Spinal cord compression requires immediate treatment with intravenously administered corticosteroids and pain relievers, as well as prompt referral to an oncologist for further treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018806

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  18 in total

1.  Complete paraplegia with diffuse osteolytic skeletal metastases: an uncommon presentation of carcinoma of the prostate.

Authors:  Akshat Gupta; Nitesh Gahlot; Poonam Elhence
Journal:  Spinal Cord Ser Cases       Date:  2020-04-22

2.  Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer.

Authors:  Meng Zhang; Ali Mahta; Ryan Y Kim; Serra Akar; Santosh Kesari
Journal:  Med Oncol       Date:  2011-03-20       Impact factor: 3.064

3.  Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.

Authors:  Steven R Barthel; Jacyln D Gavino; Georg K Wiese; Jennifer M Jaynes; Javed Siddiqui; Charles J Dimitroff
Journal:  Glycobiology       Date:  2008-07-22       Impact factor: 4.313

4.  Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis.

Authors:  Hayrettin Sahin; Uğur Aflay; Sabri Batun; Mehmet Kamuran Bircan
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

5.  Dissemination of prostate adenocarcinoma to the skull base mimicking giant trigeminal schwannoma: anatomic relevance of the extradural neural axis component.

Authors:  Jaime Gasco; Yvonne Kew; Andrew Livingston; James Rose; Yi Jonathan Zhang
Journal:  Skull Base       Date:  2009-11

6.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.

Authors:  Dominic Pilon; Ajay S Behl; Lorie A Ellis; Marie-Noëlle Robitaille; Patrick Lefebvre; Nancy A Dawson
Journal:  Am Health Drug Benefits       Date:  2017-05

7.  Isolated brain metastases as first site of recurrence in prostate cancer: case report and review of the literature.

Authors:  J Craig; J Woulfe; J Sinclair; S Malone
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

Review 8.  Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer.

Authors:  Eliane Gouvêa de Oliveira Barros; Nathalia Meireles Da Costa; Celia Yelimar Palmero; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti; Antonio Palumbo
Journal:  World J Urol       Date:  2018-07-06       Impact factor: 4.226

Review 9.  Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Authors:  George Orphanos; Alexandros Ardavanis
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

10.  Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease.

Authors:  George Orphanos; George Ioannidis; Michael Michael; George Kitrou
Journal:  Med Oncol       Date:  2008-10-02       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.